This is an aggregated industry headline. Read the full story at FiercePharma →
Novartis gains full FDA nod for Fabhalta in kidney disorder IgAN
The FDA has converted its accelerated approval for Novartis' Fabhalta into a full blessing to treat patients with immunoglobulin A nephropathy (IgAN). The drug is endorsed to slow kidney function decline in adults at risk of disease progression.
By FiercePharma
· Jul 18, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Thera…
The WeekBriefing
The European Commission cleared Novo Nordisk’s oral Wegovy, giving the company a head start over Eli Lilly’s s…
The WeekSTAT News ↗
"The real opportunity is to move beyond policies and narratives that pit specialties against one another," pre…